Press-release for stocks in the health technology sector for PPRUY

| -8.75% | O: 0.43% H: 0.45% C: 0.45%
PPRUY | News | $36.0023 220K

| -9.63% | O: -0.73% H: 0.41% C: 0.1%
BHC | $8.69 1.05% 400K

| -16.68% | O: -0.29% H: 3.25% C: 1.43%
ALC | $79.46 1.26% 250K

| -4.41% | O: -0.48% H: 0.99% C: 0.49%
distribution one system key growth market

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Published: 2024-03-18 (Crawled : 11:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -21.46% | O: -0.49% H: 2.65% C: 2.65%
PPRUY | News | $36.0023 220K

| -22.45% | O: -0.43% H: 0.02% C: -0.5%
PHGE | News | $0.2813 -4.9% 12K

| -23.5% | O: 1.09% H: 3.38% C: -2.7%
million acquisition therapeutics

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -17.97% | O: 1.5% H: 1.23% C: 1.05%
PPRUY | News | $36.0023 220K

| -19.23% | O: 0.81% H: 0.22% C: -0.18%
PHGE | News | $0.2813 -4.9% 12K

| 21.16% | O: 211.55% H: 18.75% C: -4.46%
million therapeutics agreement

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -21.79% | O: -0.59% H: 0.27% C: -1.83%
PPRUY | News | $36.0023 220K

| -21.79% | O: -1.85% H: 0.2% C: -0.07%
PCVX | $60.72 0.17% 150K

| -12.94% | O: 0.2% H: 0.18% C: -0.42%
STRO M | $3.745 -0.66% 67K

| -23.23% | O: 0.2% H: 1.81% C: -3.43%
vax-24 disease pneumococcal study

Vaxcyte Looks to Raise $750M in Latest Public Offering
Published: 2024-02-02 (Crawled : 17:00) - biospace.com/
PPRUF | News | $358.55 1.5K

| -11.32% | O: -0.32% H: 1.62% C: 0.05%
PPRUY | News | $36.0023 220K

| -12.8% | O: -1.16% H: 0.0% C: -0.44%
SNY | News | $46.135 1.64% 270K

| -6.09% | O: -0.93% H: 0.0% C: 0.0%
offering

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -12.79% | O: 0.92% H: 0.76% C: -1.38%
PPRUY | News | $36.0023 220K

| -13.45% | O: -0.55% H: 1.4% C: 1.28%
PCVX | $60.72 0.17% 150K

| -2.92% | O: 0.26% H: 6.59% C: 6.23%
STRO M | $3.745 -0.66% 67K

| -19.15% | O: -0.43% H: 6.84% C: 6.62%
vax-31 disease pneumococcal study

Vaxcyte Appoints Whitney Jones as Chief People Officer
Published: 2024-01-16 (Crawled : 21:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -7.74% | O: -2.87% H: 0.1% C: -0.62%
PPRUY | News | $36.0023 220K

| -7.23% | O: -3.45% H: 0.61% C: 0.53%
PCVX | $60.72 0.17% 150K

| 1.1% | O: -1.81% H: 3.73% C: 3.69%
STRO M | $3.745 -0.66% 67K

| -1.81% | O: -2.07% H: 8.71% C: 8.44%
jones

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -14.2% | O: -1.72% H: 1.77% C: -1.05%
PPRUY | News | $36.0023 220K

| -13.08% | O: -1.13% H: 1.81% C: 0.95%
PCVX | $60.72 0.17% 150K

| -2.97% | O: -2.53% H: 0.56% C: -4.66%
STRO M | $3.745 -0.66% 67K

| -14.41% | O: -4.28% H: 0.0% C: -17.88%
pneumococcal vaccine update potential

Vaxcyte Appoints Jacks Lee to Board of Directors
Published: 2023-11-28 (Crawled : 14:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -18.51% | O: -1.83% H: 1.83% C: -2.33%
SNYNF | News | $92.7 600K

| -2.28% | O: -1.89% H: 0.02% C: 0.02%
PPRUY | News | $36.0023 220K

| -18.54% | O: -2.83% H: 1.05% C: 0.51%
PCVX | $60.72 0.17% 150K

| 24.54% | O: -1.82% H: 1.91% C: 1.75%
STRO M | $3.745 -0.66% 67K

| 66.67% | O: 6.14% H: 1.24% C: -5.79%
SNY | News | $46.135 1.64% 270K

| -4.49% | O: -1.41% H: 0.87% C: 0.0%
GTHX | $4.165 -0.12% 200K

| 154.27% | O: -0.61% H: 4.91% C: 3.68%

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -18.51% | O: -1.83% H: 1.83% C: -2.33%
PPRUY | News | $36.0023 220K

| -18.54% | O: -2.83% H: 1.05% C: 0.51%
PCVX | $60.72 0.17% 150K

| 24.54% | O: -1.82% H: 1.91% C: 1.75%
STRO M | $3.745 -0.66% 67K

| 66.67% | O: 6.14% H: 1.24% C: -5.79%
vaccine control biopharma agreement

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -16.85% | O: -1.41% H: 1.77% C: -1.32%
PPRUY | News | $36.0023 220K

| -16.35% | O: 1.28% H: 0.21% C: -1.4%
PCVX | $60.72 0.17% 150K

| 23.38% | O: 0.59% H: 0.63% C: -5.62%
STRO M | $3.745 -0.66% 67K

| 56.38% | O: 4.12% H: 0.0% C: -11.07%
vax-31 disease pneumococcal study

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -13.84% | O: 4.04% H: 0.01% C: -0.94%
PPRUY | News | $36.0023 220K

| -15.6% | O: -0.66% H: 1.13% C: 0.77%
PCVX | $60.72 0.17% 150K

| 29.39% | O: -0.52% H: 7.4% C: 4.69%
STRO M | $3.745 -0.66% 67K

| 41.79% | O: 1.49% H: 0.74% C: -3.68%
business update financial results

Freshfields Builds US M&A Advisory Capability With Latham & … – Law.com International
Published: 2023-11-01 (Crawled : 10:00) - spacfeed.com
PPRUF | News | $358.55 1.5K

| -12.85% | O: -1.43% H: 0.56% C: -0.34%
PPRUY | News | $36.0023 220K

| -10.91% | O: -0.74% H: 1.12% C: 0.92%
HEPA | $2.1118 12K

| -54.82% | O: -3.85% H: 4.23% C: -2.0%
international

IPO Busts Have Lawyers Watching for Shareholder Stock Drop Suits – Bloomberg Law
Published: 2023-11-01 (Crawled : 10:00) - spacfeed.com
PPRUF | News | $358.55 1.5K

| -12.85% | O: -1.43% H: 0.56% C: -0.34%
PPRUY | News | $36.0023 220K

| -10.91% | O: -0.74% H: 1.12% C: 0.92%
HEPA | $2.1118 12K

| -54.82% | O: -3.85% H: 4.23% C: -2.0%
drop

Accenture boosts project consulting and healthcare marketing … – Investing.com
Published: 2023-11-01 (Crawled : 09:00) - spacfeed.com
PPRUF | News | $358.55 1.5K

| -12.85% | O: -1.43% H: 0.56% C: -0.34%
PPRUY | News | $36.0023 220K

| -10.91% | O: -0.74% H: 1.12% C: 0.92%
HEPA | $2.1118 12K

| -54.82% | O: -3.85% H: 4.23% C: -2.0%

VIC Acquistion Manager – Kering
Published: 2023-11-01 (Crawled : 08:00) - spacfeed.com
PPRUF | News | $358.55 1.5K

| -12.85% | O: -1.43% H: 0.56% C: -0.34%
PPRUY | News | $36.0023 220K

| -10.91% | O: -0.74% H: 1.12% C: 0.92%
HEPA | $2.1118 12K

| -54.82% | O: -3.85% H: 4.23% C: -2.0%

Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Published: 2023-10-31 (Crawled : 20:00) - biospace.com/
PPRUF | News | $358.55 1.5K

| -10.45% | O: 2.15% H: 0.59% C: 0.59%
PPRUY | News | $36.0023 220K

| -11.58% | O: -0.56% H: 0.2% C: -0.2%
ALRN | $5.0 22K

| 338.52% | O: 2.26% H: 20.23% C: -6.22%
lung acquisition therapeutics

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-10-19 (Crawled : 12:30) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -17.42% | O: -0.57% H: 1.09% C: 0.98%
PPRUY | News | $36.0023 220K

| -15.86% | O: 1.4% H: 0.53% C: -0.81%
PCVX | $60.72 0.17% 150K

| 35.63% | O: 0.24% H: 2.54% C: 0.78%
STRO M | $3.745 -0.66% 67K

| 7.95% | O: -0.28% H: 0.0% C: -6.27%
vax-31 fda drug disease pneumococcal clearance application

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -17.42% | O: -0.57% H: 1.09% C: 0.98%
PPRUY | News | $36.0023 220K

| -15.86% | O: 1.4% H: 0.53% C: -0.81%
JNJ | News | $146.315 0.4% 1.3M

| -5.09% | O: -0.73% H: 0.0% C: 0.0%
RPRX | $27.93 0.14% 300K

| 0.55% | O: 0.15% H: 3.45% C: 2.22%
PTCT | $25.005 1.28% 120K

| 22.73% | O: 3.46% H: 19.19% C: 11.13%
pharma royalty evrysdi agreement

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
PPRUF | News | $358.55 1.5K

| -16.59% | O: -1.4% H: 2.43% C: 0.02%
PPRUY | News | $36.0023 220K

| -16.83% | O: -2.01% H: 2.36% C: 1.96%
APLS | $47.0 -1.07% 240K